Suppr超能文献

成人与儿童肥胖症的精准医学:临床视角

Precision medicine in adult and pediatric obesity: a clinical perspective.

作者信息

Bomberg Eric M, Ryder Justin R, Brundage Richard C, Straka Robert J, Fox Claudia K, Gross Amy C, Oberle Megan M, Bramante Carolyn T, Sibley Shalamar D, Kelly Aaron S

机构信息

Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota, Minneapolis, 717 Delaware Street SE, Room 371, Minneapolis, MN 55414, USA.

Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.

出版信息

Ther Adv Endocrinol Metab. 2019 Jul 27;10:2042018819863022. doi: 10.1177/2042018819863022. eCollection 2019.

Abstract

It remains largely unknown as to why some individuals experience substantial weight loss with obesity interventions, while others receiving these same interventions do not. Person-specific characteristics likely play a significant role in this heterogeneity in treatment response. The practice of precision medicine accounts for an individual's genes, environment, and lifestyle when deciding upon treatment type and intensity in order to optimize benefit and minimize risk. In this review, we first discuss biopsychosocial determinants of obesity, as understanding the complexity of this disease is necessary for appreciating how difficult it is to develop individualized treatment plans. Next, we present literature on person-specific characteristics associated with, and predictive of, weight loss response to various obesity treatments including lifestyle modification, pharmacotherapy, metabolic and bariatric surgery, and medical devices. Finally, we discuss important gaps in our understanding of the causes of obesity in relation to the suboptimal treatment outcomes in certain patients, and offer solutions that may lead to the development of more effective and targeted obesity therapies.

摘要

为何有些人在肥胖干预措施下体重显著减轻,而接受相同干预的其他人却没有,这在很大程度上仍然未知。个体特异性特征可能在这种治疗反应的异质性中发挥重要作用。精准医学的实践在决定治疗类型和强度时会考虑个体的基因、环境和生活方式,以优化益处并将风险降至最低。在本综述中,我们首先讨论肥胖的生物心理社会决定因素,因为了解这种疾病的复杂性对于认识制定个性化治疗方案有多困难是必要的。接下来,我们展示关于与各种肥胖治疗(包括生活方式改变、药物治疗、代谢和减肥手术以及医疗设备)的体重减轻反应相关并可预测该反应的个体特异性特征的文献。最后,我们讨论在理解肥胖原因与某些患者治疗效果欠佳之间的重要差距,并提供可能导致开发更有效和针对性更强的肥胖治疗方法的解决方案。

相似文献

1
Precision medicine in adult and pediatric obesity: a clinical perspective.
Ther Adv Endocrinol Metab. 2019 Jul 27;10:2042018819863022. doi: 10.1177/2042018819863022. eCollection 2019.
3
Towards precision medicine in bariatric surgery prescription.
Rev Endocr Metab Disord. 2023 Oct;24(5):961-977. doi: 10.1007/s11154-023-09801-9. Epub 2023 May 2.
4
Bariatric surgery: an evidence-based analysis.
Ont Health Technol Assess Ser. 2005;5(1):1-148. Epub 2005 Jan 1.
5
Treatment Options for Severe Obesity in the Pediatric Population: Current Limitations and Future Opportunities.
Obesity (Silver Spring). 2018 Jun;26(6):951-960. doi: 10.1002/oby.22196. Epub 2018 May 7.
8
Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab. 2017 Mar 1;102(3):709-757. doi: 10.1210/jc.2016-2573.
9
Working toward precision medicine approaches to treat severe obesity in adolescents: report of an NIH workshop.
Int J Obes (Lond). 2018 Nov;42(11):1834-1844. doi: 10.1038/s41366-018-0231-x. Epub 2018 Oct 3.
10
Contemporary medical, device, and surgical therapies for obesity in adults.
Lancet. 2023 Apr 1;401(10382):1116-1130. doi: 10.1016/S0140-6736(22)02403-5. Epub 2023 Feb 9.

引用本文的文献

1
Incretin-based therapies for the treatment of obesity-related diseases.
NPJ Metab Health Dis. 2024 Nov 6;2(1):31. doi: 10.1038/s44324-024-00030-5.
3
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.
Pharmaceuticals (Basel). 2025 Mar 12;18(3):399. doi: 10.3390/ph18030399.
6
Semaglutide for weight loss: unanswered questions.
Front Endocrinol (Lausanne). 2024 Jun 5;15:1382814. doi: 10.3389/fendo.2024.1382814. eCollection 2024.
8
A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss.
Cureus. 2024 May 2;16(5):e59558. doi: 10.7759/cureus.59558. eCollection 2024 May.
10
An interpretable predictive deep learning platform for pediatric metabolic diseases.
J Am Med Inform Assoc. 2024 May 20;31(6):1227-1238. doi: 10.1093/jamia/ocae049.

本文引用的文献

2
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
Ann Intern Med. 2019 May 21;170(10):682-690. doi: 10.7326/M18-1605. Epub 2019 Apr 23.
3
Mobile Health Applications in Weight Management: A Systematic Literature Review.
Am J Prev Med. 2019 Jun;56(6):894-903. doi: 10.1016/j.amepre.2018.12.005. Epub 2019 Apr 17.
4
A systematic review of tailored eHealth interventions for weight loss.
Digit Health. 2019 Feb 5;5:2055207619826685. doi: 10.1177/2055207619826685. eCollection 2019 Jan-Dec.
5
Long and Short of It: Early Response Predicts Longer-Term Outcomes in Pediatric Weight Management.
Obesity (Silver Spring). 2019 Feb;27(2):272-279. doi: 10.1002/oby.22367.
7
Obesity as a Disease: The Obesity Society 2018 Position Statement.
Obesity (Silver Spring). 2019 Jan;27(1):7-9. doi: 10.1002/oby.22378.
10
New Insights Regarding Genetic Aspects of Childhood Obesity: A Minireview.
Front Pediatr. 2018 Oct 4;6:271. doi: 10.3389/fped.2018.00271. eCollection 2018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验